Master AI image and video generation by structuring prompts with JSON, eliminating trial and error for consistent, ...

Critical flaws affecting core components and extensions in PostgreSQL and MariaDB could allow remote code execution. The bugs ...

Adrian has been writing, critiquing, and thinking about games since he first picked up an N64 controller many years ago. These days he writes reviews, news, and features for Game Rant and believes ...

Minecraft Create Aeronautics is a brand new mod that brings loads of new mechanics to the already-popular mod, Create. This particular mod was in development for nearly four years, with its pre-alpha ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Oracle announced a suite of agentic AI capabilities integrated directly into Oracle AI ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Pills, tablets and capsules on world map with charts blue background. International ...

Karan Mahajan’s new novel, “The Complex,” tracks the fortunes of a political family in a rapidly changing India. By Jonathan Dee Jonathan Dee is the author of eight novels, most recently “Sugar Street ...

The second studio album from the biggest girl group in K-Pop is available now on Complex in multiple editions. The 15 Best K-Pop and Rap Collaborations of All Time From Jennie's electrifying duet with ...

Feb 27 (Reuters) - Flagship-backed Generate Biomedicines' shares fell more than 6% in their Nasdaq debut on Friday, giving the drug developer a valuation of $1.91 billion, as lingering market ...

Despite wide availability of biologic drugs for asthma, use of these injectable medicines remains low — patients just dislike frequent injections. Generate Biomedicine’s lead drug candidate could ...

Generate:Biomedicines is the latest biotech to benefit from a renewed appetite from investors for publicly listed drug developers. Generate—which will list its stock on the Nasdaq this morning under ...

Feb 26 (Reuters) - Generate Biomedicines said on Thursday that it raised $400 million in its U.S. initial public offering, pricing shares of the U.S.-based drug developer at $16 each. The offering ...